Enhancer of Zeste Homolog 2 (EZH2)

Overview

EZH2 (Enhancer of Zeste Homolog 2) is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), a conserved chromatin-modifying enzyme complex that plays a fundamental role in epigenetic gene regulation. EZH2 functions as a histone methyltransferase, catalyzing the trimethylation of histone H3 at lysine 27 (H3K27me3), a repressive chromatin mark that silences target gene expression. Through this mechanism, EZH2 governs critical biological processes including cell differentiation, proliferation, and stem cell identity. Its activity is tightly regulated during normal development, but dysregulation — through overexpression, gain-of-function mutation, or altered complex stoichiometry — has been broadly implicated in oncogenesis, tumor progression, and therapy resistance across a wide range of malignancies.

Beyond its canonical role in cancer, EZH2 has emerged as a mediator of disease-relevant epigenomic reprogramming in non-malignant contexts, including vascular pathology and metabolic disease. As a druggable epigenetic target, EZH2 has attracted considerable pharmacological interest, with selective inhibitors such as Tazemetostat (the first FDA-approved EZH2 inhibitor) and investigational compounds such as GSK-126 (gsk-2816126) demonstrating therapeutic potential across oncologic and inflammatory indications. Its position at the intersection of the epigenome, immune evasion, cell cycle regulation, and DNA methylation makes EZH2 one of the most extensively studied epigenetic regulators in contemporary biomedical research.

Recent Publications Summary

Recent studies have continued to position Enhancer of Zeste Homolog 2 (EZH2) as a central epigenetic regulator across diverse disease contexts, with multiple reports linking its activity to transcriptional repression through H3K27me3 and to clinically relevant phenotypes. In dengue fever, integrated bioinformatic, machine learning, and network pharmacology analyses identified EZH2 as one of three core genes significantly overexpressed in patients, alongside CXCL10 and EPHB2, suggesting potential diagnostic and therapeutic relevance; single-cell transcriptome analysis indicated that the predicted action of Qingwen Baidu Decoction was concentrated in dendritic cells, monocytes, and macrophages 42332327Jun. In hepatocellular carcinoma, network toxicology and multi-omics analyses of bisphenol A exposure also highlighted EZH2 among six hub genes upregulated in tumors, with computational docking predicting stable BPA binding to EZH2 and related cell-cycle proteins 42118483May.

Several studies focused on EZH2 as a therapeutic target in cancer and vascular disease. In diabetes-associated atherosclerosis, EZH2-mediated H3K27 trimethylation was elevated in carotid plaques and diabetic aortic endothelium, and pharmacologic inhibition with GSK-126 reduced endothelial-to-mesenchymal transition (EndMT) and atherosclerotic burden in diabetic mice; in cultured human aortic endothelial cells, EZH2 blockade by GSK-126 or shRNA reversed EndMT-associated transcriptional programs, including COL4A1 and NR2F2 42213823May. In pancreatic neuroendocrine neoplasms, EZH2 was reported to be upregulated in tissues and cell lines, where knockdown or GSK126 suppressed proliferation and induced ferroptosis in vitro and in vivo, at least in part through inhibition of the PI3K/AKT/mTOR pathway; the study also identified HMGCS1 as a potential mediator of resistance to EZH2 inhibition and showed that combining GSK126 with everolimus enhanced antitumor effects 42013002Apr. In rhabdomyosarcoma, multi-omics analyses identified EZH2 as a central driver of radioresistance, with radioresistant models showing downregulation of EZH2 target genes and subtype-specific epigenetic rewiring, supporting EZH2-linked resistance to radiotherapy 42225614Jun.

Other reports described EZH2-directed epigenetic strategies that modulate tumor immunity and stromal biology. In castration-resistant prostate cancer, integrative multi-omics analyses revealed a compensatory switch between DNA methylation and H3K27me3 repression, with DNMT inhibitors inducing EZH2-dependent H3K27me3 accumulation at the ADAMTS1 locus; dual targeting of DNMTs and EZH2 reactivated ADAMTS1, promoted collagen degradation, suppressed FAK/MAPK mechanotransduction, reversed epithelial-mesenchymal transition, and enhanced cytotoxic CD8+ T cell infiltration while reducing immunosuppressive macrophages and Tregs 42313934Jun. In a separate study, the EZH2-selective small molecule C36 was shown to inhibit EZH2/PRC2 through a novel SAM non-competitive mechanism, reduce H3K27 trimethylation and PRC2 target gene expression, and exhibit low hematotoxicity; multi-omics analyses further identified direct regulation of IFNB1 by EZH2/PRC2, and combination with PD-1 blockade was explored in syngeneic lung cancer models 42314051Jun. Additional work in osteosarcoma linked cisplatin-induced oxidative stress and reactive oxygen species to increased H3K27me3 at growth-associated genes and LATS1, implicating YAP-dependent epigenetic adaptation in survival after chemotherapy, although the abstract only partially details EZH2 involvement 41980058Apr.

What Changes, What Holds

1. EZH2 now appears as a disease-linked biomarker and exposure-responsive node beyond cancer
NEW DIRECTION Integrated analyses in dengue and hepatocellular carcinoma extend EZH2’s relevance into infectious disease and toxicant-associated tumor biology, but they do not displace its established role as a chromatin repressor. The main implication is that EZH2 may be useful as a cross-context readout of inflammatory or carcinogenic reprogramming, with the dengue work still computational and the BPA study suggesting a possible direct interaction that would need experimental validation 42332327Jun42118483May.

2. EZH2 inhibition is being pushed from tumor control into vascular remodeling and ferroptosis-linked combination therapy
NEW DIRECTION Work in diabetic atherosclerosis adds a non-malignant disease mechanism to the baseline account, showing that EZH2-driven H3K27me3 can support endothelial-to-mesenchymal transition and plaque burden, while inhibition reverses that program 42213823May. In pancreatic neuroendocrine neoplasms, the same target is tied to growth suppression and ferroptosis, with a proposed resistance mediator and synergy with everolimus 42013002Apr. Together these findings broaden therapeutic framing, but remain preclinical and context-specific.

3. EZH2-linked epigenetic plasticity may underlie resistance and immune escape, but the dual-targeting strategy remains provisional
NEW DIRECTION The prostate cancer study suggests a compensatory relationship between DNA methylation and H3K27me3 that can be exploited by co-inhibiting DNMTs and EZH2, which would extend the baseline’s epigenetic-intersection theme into stromal remodeling and antitumor immunity 42313934Jun. The lung cancer work further supports EZH2/PRC2 as an immunotherapy-relevant regulator through a new small-molecule mechanism 42314051Jun. These are mechanistically interesting, but they do not yet establish clinical utility, and the osteosarcoma report only partially implicates EZH2 41980058Apr.

Overview update candidates: EZH2 as a biomarker in dengue and BPA-associated hepatocellular carcinoma; EZH2 in diabetic atherosclerosis and EndMT; EZH2-linked ferroptosis and combination therapy in pancreatic neuroendocrine neoplasms; EZH2-dependent epigenetic compensation affecting stromal biology and immune infiltration in prostate cancer; a novel SAM non-competitive EZH2/PRC2 inhibitor mechanism with PD-1 combination rationale.